Asimov
Intelligent design of living systems
Intelligent design of living systems
Asimov is a biotechnology startup with the slogan "Intelligent design of living systems," focusing on developing tools for programming living cells. Founded in 2017 and headquartered in the United States, Asimov integrates mammalian synthetic biology, computer-aided design, and machine learning to advance the design and manufacture of biologics and gene therapies. The company's latest milestone was a $175.00M Series B investment on 05 January 2023, which attracted support from prominent investors including Pillar, Casdin Capital, KdT Ventures, Andreessen Horowitz (a16z), Horizons Ventures, Fidelity, and the Canada Pension Plan Investment Board. Asimov's innovative approach and the strong support from reputable investors position the company as a key player in the biotechnology industry.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series B | $175.00M | 7 |
|
05 Jan 2023 |
| Series A | $25.00M | 1 |
|
01 Jan 2020 |
| Seed Round | $5.00M | 2 |
|
19 Dec 2017 |
| Seed Round | Unknown | - | 17 Jan 2017 |
No recent news or press coverage available for Asimov.
We care about your data, and we'd love to use cookies make your experience better.
